The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy
出版年份 2017 全文链接
标题
The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy
作者
关键词
Cancer treatment, HT29 cells, Phosphorylation, DNA damage, Apoptosis, Pancreatic cancer, Cell cycle and cell division, Chemotherapeutic agents
出版物
PLoS One
Volume 12, Issue 5, Pages e0178221
出版商
Public Library of Science (PLoS)
发表日期
2017-05-31
DOI
10.1371/journal.pone.0178221
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Naiyer A. Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
- (2016) Roberta Visconti et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Survival effects of adjuvant gemcitabine plus S-1 chemotherapy on pancreatic carcinoma stratified by preoperative resectability status
- (2016) Yoshiaki Murakami et al. JOURNAL OF SURGICAL ONCOLOGY
- Pancreatic cancer
- (2016) Terumi Kamisawa et al. LANCET
- The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients
- (2016) Mei-Chin Hsieh et al. Cancer Medicine
- Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study
- (2015) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- ATM and ATR as therapeutic targets in cancer
- (2015) Anika Maria Weber et al. PHARMACOLOGY & THERAPEUTICS
- CBP-93872 Inhibits NBS1-Mediated ATR Activation, Abrogating Maintenance of the DNA Double-Strand Break-Specific G2 Checkpoint
- (2014) T. Hirokawa et al. CANCER RESEARCH
- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
- (2013) Yasuhide Yamada et al. LANCET ONCOLOGY
- Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy?
- (2012) Hidemasa Goto et al. CANCER SCIENCE
- New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: Implications for Cancer Therapy
- (2012) Razmik Mirzayans et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Checkpoints meet the transcription at a novel histone milestone (H3-T11)
- (2011) Midori Shimada et al. CELL CYCLE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer therapy with checkpoint inhibitors: what, where and when?
- (2011) Michelle D. Garrett et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
- (2010) T. Doi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
- (2010) Cynthia X. Ma et al. TRENDS IN MOLECULAR MEDICINE
- The DNA-damage response in human biology and disease
- (2009) Stephen P. Jackson et al. NATURE
- Chk1 Is a Histone H3 Threonine 11 Kinase that Regulates DNA Damage-Induced Transcriptional Repression
- (2008) Midori Shimada et al. CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now